Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 225 (ZNF225)
- Target
- ZNF225
- Molecular classification
- Transcription factor, C2H2-type zinc finger protein
01
Overview
Zinc finger protein 225 (ZNF225) is a human protein encoded by the ZNF225 gene and is classified as a C2H2-type zinc finger transcription factor[3][4][5][1]. It is predicted to function primarily in the regulation of transcription as a DNA-binding transcriptional activator or repressor, specifically for genes transcribed by RNA polymerase II[1][3][6]. ZNF225 is part of a large family of zinc finger proteins that act as key regulators of gene expression, influencing a range of cellular processes[2][3]. While ZNF225 has no established function as a drug target, it has been identified as part of multi-gene prognostic models in cancers such as esophageal carcinoma, where its expression correlates with patient risk and prognosis[2]. There is limited direct functional characterization in disease beyond these correlative cancer studies, and no drugs or therapies currently target ZNF225 directly[2].
- Other names
- ZNF225Zinc finger protein 225
02
Mechanism of action
Not applicable (no direct targeting drugs identified)
03
Biological functions
Regulation of transcription by RNA polymerase IIDNA bindingRNA polymerase II cis-regulatory region sequence-specific DNA binding activity
04
Disease associations
Cancer (notably implicated as a prognostic marker/gene signature in cancers such as esophageal carcinoma and suggested in hepatocellular carcinoma)Other (broad role in gene regulation with potential implications in diverse pathologies via altered transcriptional regulation, but no established direct disease causality beyond cancer-related associations)
05
Safety considerations
Not established (no evidence of safety concerns or therapeutic challenges specifically related to ZNF225 modulation; it is not an established direct therapeutic target)
06
Interacting drugs
None known
07
Biomarkers
Prognostic marker for esophageal carcinoma (in gene signature models identifying risk/prognostic subgroups)
Beyond the preview
Go deeper on Zinc finger protein 225 (ZNF225).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 225 (ZNF225).